Table 1.
Clinicopathologic Characteristics of Patients With Atypical EGFR Mutations and HER2 Alterations
| Characteristic | a-EGFR (N = 55) | HER2 (N = 31) |
| Sex | ||
| Male | 17 (31) | 10 (32) |
| Female | 38 (69) | 21 (68) |
| Race | ||
| White | 39 (71) | 20 (65) |
| Black | 3(5) | 0 |
| Asian | 7(13) | 1 (3) |
| Hispanic | 0 | 2(6) |
| Other | 6(11) | 8 (26) |
| Age (y), median (range) | 62 (38–91) | 62 (47–80) |
| Smoking Status (pack-years) | ||
| Never | 32 (58) | 23 (76) |
| Light (≤10) | 7(13) | 3(8) |
| Heavy (>10) | 16 (29) | 5 (16) |
| Histology | ||
| Adenocarcinoma | 53 (96) | 30 (97) |
| Adenosquamous | 1 (2) | 1 (3) |
| Squamous | 1 (2) | 0 |
| Stage at Diagnosis | ||
| I | 4(8) | 0 |
| II | 2(4) | 1 (3) |
| III | 2(4) | 3(10) |
| IV | 47 (85) | 27 (87) |
| Brain metastasesa | 16 (27) | 9 (29) |
Data are presented as n (%) unless otherwise indicated. All disease was staged by magnetic resonance imaging.
Abbreviation: a-EGFR = atypical EGFR.
a
Brain metastases at time of stage IV disease.